Without an anti-Covid vaccine, Sanofi publishes solid results driven by Dupixent

Posted 4 Feb. 2022 at 16:56Updated 4 Feb. 2022 at 17:29

Sanofi ignores the Covid. Bullied for missing the vaccine train against the disease that has been poisoning the world for two years, the French pharmaceutical group ended its 2021 financial year with consolidated sales of 37.76 billion euros, up 4.8 % over one year, and earnings per share of 6.56 euros, up 15.5%. This will allow the company to pay a dividend of 3.33 euros to shareholders, for a total amount of 4 billion euros. Something to console them for not having seen their group at the forefront in the fight against the Covid.

“2021 ends with a solid performance from Sanofi in the fourth quarter, driven by double-digit sales growth from Dupixent, which are breaking new records every quarter,” said group chief executive Paul Hudson. during the presentation of the annual results on Friday. In fact, Sanofi really became the “Dupixent Company” last year. Sales of this product against eczema increased by 52.7%, to 5.25 billion euros, so that it now represents 14% of the group’s consolidated turnover.

Leave a Reply

Your email address will not be published. Required fields are marked *